Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone

César A. Restrepo Valencia¹, Gilberto Manjarrés Iglesias¹-², Consuelo Vélez Álvarez³

Abstract

Objective: To determine whether a treatment with spironolactone can correct chronic idiopathic hypokalemia for patients with chronic kidney disease undergoing treatment with peritoneal dialysis.

Design: Interventional study without control group.

Patients: Patients with chronic kidney disease over 18 years old, undergoing treatment with peritoneal dialysis for over 1 year; with reported diuresis of less than 100 ml in 24 hours and in whom chronic idiopathic hypokalemia was diagnosed.

Materials and methods: All patients were tested for known causes of hypokalemia; once these causes were discarded we initiated treatment with spironolactone with an initial dose of 25 mgs per day and a monthly increase of 25 mgs until a maximum dose of 200 mg per day. Serum potassium was measured monthly and dialyzed potassium was measured every 6 months.

Results: 20 patients fulfilled the requirements for inclusion. Four patients (20%) developed hyperkalemia and had to stop the treatment. For the remaining 16 patients initial potassium of 2.84 was measured, 6 months later it was elevated to 3.40; 3.37 after 12 months; 3.58 after 18 months and 3.9 after 22 months, these values were statistically significant ($p < 0.05$). 12 episodes of peritonitis occurred for the 16 patients, representing an incidence of 1 episode per 19 patients month. The average dose of spironolactone used after 3 months was 65 mgs; 67 mgs after 6 months; 75 mgs after 12 months; 60 mgs after 18 months and 68 mgs after 22 months. In the 22 months follow up, 5 (25%) patients were withdrawn for motives not related to therapy and 7 of the 16 (43.75%) patients passed away.

Conclusions: Hypokalemia is a cause of great mortality for patients undergoing treatment with peritoneal dialysis; in addition to its own risks it also facilitates the development of peritonitis that requires additional therapeutic interventions. We suggest that could Spironolactone diminish the intestinal loss of potassium but may cause hyperkalemia so patients must be closely monitored.

Key word: chronic kidney disease, peritoneal dialysis, and hypokalemia (fuente DeCS).

Resultados del tratamiento de la hipopotasemia con espironolactona en paciente con enfermedad renal crónica en dialisis peritoneal

Resumen

Objetivo: Determinar si el tratamiento con espironolactona puede corregir la hipopotasemia crónica idiopática de pacientes con enfermedad renal crónica (ERC) en tratamiento con diálisis peritoneal.

Diseño: Estudio de intervención sin grupo control.
Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone

**Introduction**

Hypokalemia is a complication rarely reported in patients with chronic kidney disease (CKD) although its prevalence can fluctuate between 10% through 36% in reports from several studies\(^1,2\). Its etiology has been attributed to several different factors: some of them related to the underlying disease; others, to medical therapies, malnutrition and diets with low potassium intake\(^3\). Another explanation blames the transcellular distribution of potassium stimulated by insulin (in response to peritoneal glucose)\(^4\), loss of potassium through urine, sweat and peritoneum specially when the number of exchanges is high and residual kidney function is presented\(^5\). In a few patients the etiology is idiopathic; we believe the intestinal loss of potassium may be an important cause due to the stimulation of the intestinal receptor by mineralocorticoid activity. It is our belief that blocking these receptors could prove beneficial for restoring the levels of potassium to normal.

This study describes our experience using spironolactone for the management of hypokalemia in chronic kidney disease patients undergoing peritoneal dialysis.

**Patients, materials and methods**

Patients with chronic kidney disease over 18 years old, undergoing treatment with peritoneal dialysis for over 1 year; with reported diuresis of less than 100ml in 24 hours and in whom chronic idiopathic hypokalemia (more than 4 months evolution) was diagnosed.

Hypokalemia was defined as values lower than 3,5mEq/L. Demographic variables were analyzed and all patients were evaluated for initial KT/V and Test of Peritoneal Equilibrium. These variables were also analyzed at the end of the study and the last registered value was used for the patients who passed away or were removed from treatment due to hyperkalemia or other reasons.

A high potassium intake diet was implemented in all patients; explainable causes of hypokalemia were...
discarded such as chronic diarrheal syndrome, repetition emesis, excessive sweating, excessive mineralocorticoids and the intake of medications than can cause hypokalemia (Diuretics, B2 adrenergics and xantines). We added an angiotensin converting enzyme inhibitor (ACE inhibitor) or an angiotensin II receptor antagonist (ARBs) to the treatment for all patients without low blood pressure values. Blood pressure was registered monthly and for its control in case high values were found an ACE inhibitor or an ARB was added in the first place, followed by a calcium channel blocker or an Alfa 1 antagonist depending on the treating doctors' judgment; the goal blood pressure was set around 140/90 mmHg.

The levels for renin and aldosterone were determined for all patients as well as the dialyzed 24 hours potassium excretion. 24 hour potassium in urine was not determined due to the fact that all patients were anuric (diuresis less tan 100ml/24 hours); 24 hours fecal potassium was not determined either due to the difficulties at obtaining and processing the samples.

Patients received spironolactone with an initial dose of 25 mg per day and a monthly increase of 25 mg until a maximum dose of 200 mgs per day. In case a potassium level was found higher than 4.5 meq/L the dose was reduced by 25 mgs; higher than 5.0 meq/L it was reduced by 50 mgs and if it was found higher tan 5.5 meq/L the treatment was suspended. Serum potassium was measured monthly and dialyzed potassium was measured every 6 months. The study was extended for 22 months for the patients who achieved the time of evaluation, corresponding to the last cut of the research data.

Design
Interventional study without a control group. All patients gave their written consent before taking part in the study.

Results
20 patients met the inclusion criteria, 12 (60%) in CAPD program and 8 (40%) in APD. 4 men and 16 women with a mean age of: 65.7 +/- 9.08, CKD etiology: 12 (60%) diabetic nephropathy, 4 (20%) hypertensive nephropathy, 4 (20%) unknown etiology.

Four (20%) patients required the discontinuation of therapy due to the appearance of hyperkalemia (mean plasma potassium at suspension of 5.905 +/- 0.34 mEq/L) without clinical or electrocardiographic changes; all within the first 9 months of therapy and an average of 5.25 months; with an average dose of spironolactone at the time of suspension of 31.25 +/- 12.5 mg. Interestingly during the 14 months follow up of this group, no patient passed away or presented hypokalemia. The age of these patients was 65.25 +/- 8.42 years, while the group that did not present 65.81 +/- 9.50 without statistically significant differences.

Of 16 (80%) patients who did not develop hyperkalemia, eleven completed 6 months follow-up, 8 twelve months, six 17 months, and only four patients 22 months.

5 patients were withdrawn for reasons unrelated to therapy: two were transferred to a different health institution, one underwent renal transplant, one was transferred to hemodialysis due to refractory peritonitis. 7 of the 16 (43.75%) patients passed away during follow-up; their average serum potassium at the time of death was 3.06 +/- 0.70. 2 within the first 4 months of starting treatment; the causes of death were: 1 myocardial infarction and 1 pneumonia; the remaining 5 patients passed away between three and seven months of treatment; one at 11 months and the last at 16 months. The causes of death were: 2 hemorrhagic strokes, 2 lower limb gangrene, and one sudden death.

Only 3 patients’ had initial potassium values higher than 30 mEq in 24 hours dialysate; two of them passed away in the first 6 months follow-up. The remaining patient had a potassium dialysate of 31.58 at 6 months treatment; 35.88 at 12 months; 43.74 at 18 months and 15.7 at 22 months. The 24 hours dialysate potassium was found at an average of 26.78 +/- 15.22 for all patients; an average of 26.40 +/- 16.17 for the patients who didn't develop hyperkalemia, and an average of 28.32 +/- 12.78 for the ones who did present it. At 6 months follow up this value was
32.51 +/- 10.82 for all patients; 30.19 +/- 10.63 for the group without hyperkalemia and an elevation was found in the hyperkalemia group with an average of 42.92 +/- 2.90. This probably reflected serum potassium and indicated dialysate independent factors in the generation of changes in serum potassium. The 12 month follow up values for the group without hyperkalemia were averages of: 22.51 +/- 5.44 at 12 months; 30.91 +/- 12.87 at 18 months and 29.93 +/- 18.48 at 22 months.

The initial serum albumin was evaluated for an average of 3.15 +/- 0.39 for all patients; for deceased patients an average of 2.99 +/- 0.51 and for non deceased patients an average of (13) 3.25 +/- 0.30. Of the 7 patients who passed away six (85.71%) had low albumin values at baseline. The initial serum albumin for patients who developed hyperkalemia during treatment was an average of 3.45 +/- 0.05 and for those who didn't it was an average of 3.09 +/- 0.41. In the group of patients with improvement in the value of serum potassium, serum albumin from an initial value of 3.09 +/- 0.41 shifts to a final value of 3.09 +/- 0.54 statistically unchanged significant.

The total values of renin before treatment averaged 22.33 pg/ml; the total values for aldosterone averaged 6.51 ng/100 cc. No patient presented renin values greater than 65 pg/ml; or aldosterone values greater than 20 ng/100cc compatible with mineralocorticoid excess.

12 episodes of peritonitis occurred in 16 patients, representing an incidence of 1 episode per 19 patients month; in comparison with the total group of patients (136 on average) evaluated in the same time period and with a calculated incidence of 1 episode per 44 patients month.

The initial potassium for the 16 patients who didn't develop hyperkalemia was 2.84; at 6 months it was raised to 3.40; at 12 months 3.37; 18 months 3.58 and at 22 months it was 3.9 (Figure 1). The average dose of spironolactone used at 3 months was 65 mgs; 67 mgs at 6 months; 75 mgs at 12 months; 60 mgs at 18 months, 68 mgs at 22 months.

In order to the determine the behavior of serum potassium in the patients enrolled in the study we used the following procedure. Patients who could recei-
The value for initial KT/V was an average of 1.76 ± 0.67 for all patients, with an average age of 65.7 ± 9.08 and at the end it was 1.79 ± 0.40. The peritoneal equilibrium test was evaluated in the group of patients who did not develop hyperkalemia; 6 were found to be low transporters of glucose; 9 were high transporters of glucose; 6 were low transporters of creatinine and 9 were high transporters of creatinine. Evaluating these parameters at the end of the study we found no significant changes.

Evaluating the blood pressure variable we realized it was elevated in both groups with and without hyperkalemia but we decided not to consider it as an important variable because we allowed changes in antihypertensive therapy for patients with high cardiovascular risk. None of the side effects for spironolactone were observed such as gynecomasty and low blood pressure.

### Discussion

Hypokalemia is a rare complication in CKD patients but it is associated with significant complications with increased morbidity and mortality, even though all-cause and cardiovascular mortality can be higher in the first year of peritoneal dialysis.

Hypokalemia is also considered a risk factor for peritonitis in patients undergoing peritoneal dialysis. It could be caused by a reduction in gastrointestinal motility, with subsequent bacterial overgrowth and trans mural migration of enteric organisms. It could also be a marker of malnutrition, relating to alterations in the immune defense mechanisms.

Due to the risk that hypokalemia represents, its treatment is paramount. Various therapies have been explored, including potassium replacement therapy, sodium polystyrene sulfonate, and calcium channel blockers. Each has its own advantages and disadvantages, and the choice of therapy should be individualized based on the patient’s specific needs and comorbidities.
Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone

been tried; including increased oral intake of potassium\textsuperscript{2, 12}; Icodextrin to improve nutritional status, and generate lower insulin secretion\textsuperscript{13, 14}; potassium infusion in the bags for dialysis\textsuperscript{15-17} and mineralocorticoid blockade with mineralocorticoid receptor antagonists (MRAs).

Mineralocorticoid blockade has always been considered high risk in patients with CKD; it has been used in patients with CKD and resistant hypertension. In a group of patients without dialysis Pisoni et al obtained therapeutic efficacy, but with the risk of generating hyperkalemia, and a fall in the GFR\textsuperscript{18}. In patients undergoing dialysis therapy, Xiaoying Ni et al achieved a significant reduction in blood pressure, but 2 patients required the discontinuation of medication by the development of hyperkalemia\textsuperscript{19}. In the Dialysis Outcome Heart Failure Aldactone Study (DOHAS), Matsumoto Y, et al in patients undergoing hemodialysis, spironolactone reduced the frequency of death or hospitalization for cardio-cerebrovascular events and hyperkalemia was observed only in 1.9\% of patients\textsuperscript{20}.

In patients undergoing peritoneal dialysis with Class III and IV heart failure, the spirono lactone improvement the patients' ejection fraction, and left ventricle mass index with very low side effects such as hyperkalemia, only in one patient in the study of Taheri et al\textsuperscript{21}, and 2 in the Ito Y et al\textsuperscript{22}.

Yongsiri S et al, in a randomized, double-blind, placebo controlled trial conducted in 24 peritoneal dialysis patients with hypokalemia, evaluated the therapeutic response to 25 mgs of spironolactone for 4 weeks. They found no significant changes in serum potassium; however they did not increase the dose and the study was conducted for a very short time\textsuperscript{23}.

In our study we found that hypoalbuminemia is common in patients who were diagnosed with hypokalemia, their presence is linked with high mortality and the possible emergence of bacterial peritonitis. The absence of significant variation in the values of serum albumin between its initial and final value excludes improvement of nutritional status that explains the rise in serum potassium.

Treatment with spironolactone can correct hypokalemia, but patients must be closely monitored due to the risk of hyperkalemia, especially in anuric patients. The age of patients with treatment in the group of hyperkalemia was not different that group without hyperkalemia, important aspect because the aged patients have major possibility of this complication\textsuperscript{24}. The KT/V and age of the patients at the beginning and end of treatment was found in the recommended goals, being unlikely to contribute to potassium disturbances, their correction, and the appearance of hyperkalemia.

We suggest that hypokalemic CKD patients undergoing peritoneal dialysis may have an abnormal activity in the colon's aldosterone-sensitive epithelial sodium channels, which could result in sodium retention and increased potassium loss by digestive tract. We believe that the administration of an aldosterone antagonist (spironolactone) could reduce their losses and restore serum potassium levels.

It has been observed that the aldosterone levels in CKD patients rise gradually when their GFR is less than 50 ml/minute. The intestinal cells of the colon and small intestine may be affected by aldosterone effect, with an increase in luminal membrane permeability to sodium and a subsequent activation of new sodium channels, resulting in an increased activity and number of Na,K-ATPase pumps. The result of the above interaction is intestinal sodium retention and increased intestinal potassium loss\textsuperscript{25}.

Table 3.

<table>
<thead>
<tr>
<th>Contrast statistic (a,b)</th>
<th>POTASSIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chi-square</td>
<td>10.429</td>
</tr>
<tr>
<td>Gl</td>
<td>4</td>
</tr>
<tr>
<td>Sig. asintót.</td>
<td>.034</td>
</tr>
<tr>
<td>aKruskal-Wallis Test</td>
<td></td>
</tr>
<tr>
<td>b Aggregation variable: TIME</td>
<td></td>
</tr>
</tbody>
</table>

It is also likely that low sodium intake diets common in CKD patients undergoing dialysis therapy may reactively decrease the levels of protein type 2 11B-hydroxysteroid dehydrogenase (11 B-HSD2) in the colon; this protein degrades cortisol to cortisone, a metabolite without sodium retaining activity. Subsequently an elevation of messenger RNA levels occurs and an increased activity of the epithelial sodium channel (ENaC); this condition is mediated by the activation of the mineralocorticoid receptor.

In support of our suggestions there are studies that have shown that sodium reabsorption is an active process that occurs in the rectum and colon mucosa. This process is regulated at least in part by the mineralocorticoid receptor and results in the activation of the epithelial sodium channels. Mineralocorticoid receptor activation by fludrocortisone increases the rectal electrical potential difference, an effect that is also achieved by inhibiting the enzyme 11 B-HSD2 in rectal segments obtained from a human colon.

The relevance of extra renal 11 B-HSD2 enzymes in humans has been demonstrated in patients without renal function, in which the glycyrrhetinic acid has significantly decreased the levels of plasma potassium. Colon sodium absorption in experimental models of chronic renal failure with the 5/6 nephrectomy, increases as the GFR is reduced, accompanied by elevated expression of ENaC, an effect that may be partially mediated by the AT1 receptor agonist.

Conclusions

Hypokalemia is a cause of great mortality for patients undergoing treatment with peritoneal dialysis; in addition to its own risks it also facilitates the development of peritonitis that requires additional therapeutic interventions. We suggest that the Spironolactone could to correct hypokalemia at diminish the intestinal loss of potassium, but may cause hyperkalemia so patients must be closely monitored. Preventing malnutrition and avoiding very low sodium intake diets may contribute to prevent hypokalemia. It is necessary to design studio in which can reliably measure fecal excretion of potassium, and thus confirm our suggestion.

Compliance with ethical standards

The authors state that the study was not funded. None of the authors received research grants from company or speaker honorarium from company. None of the authors is a member of committees, and declare they have no conflicts of interest.

The study met all standards of the institutional and / or national research ethical committee, and with the 1964 Helsinki declaration and its later Amendments or comparable ethical standards.

Informed consent was obtained from all single participants included in the study.

Conflict of interests

The authors declare no conflicts of interest of any kind.

Bibliographic references


